On Friday, Taysha Gene Therapies Inc (NASDAQ: TSHA) opened higher 3.46% from the last session, before settling in for the closing price of $2.16. Price fluctuations for TSHA have ranged from $0.57 to $4.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 129.39% over the past five years. Company’s average yearly earnings per share was noted 58.59% at the time writing. With a float of $150.62 million, this company’s outstanding shares have now reached $186.96 million.
Let’s look at the performance matrix of the company that is accounted for 52 employees.
Taysha Gene Therapies Inc (TSHA) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Taysha Gene Therapies Inc is 25.20%, while institutional ownership is 64.92%. The most recent insider transaction that took place on Nov 17 ’23, was worth 163,000. In this transaction 10% Owner of this company bought 100,000 shares at a rate of $1.63, taking the stock ownership to the 16,566,667 shares. Before that another transaction happened on Aug 24 ’23, when Company’s Chief Financial Officer sold 33,000 for $2.33, making the entire transaction worth $76,890. This insider now owns 258,042 shares in total.
Taysha Gene Therapies Inc (TSHA) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 3/31/2024, the company posted -0.38 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.31) by -0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 58.59% per share during the next fiscal year.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Check out the current performance indicators for Taysha Gene Therapies Inc (TSHA). In the past quarter, the stock posted a quick ratio of 3.36. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 31.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.16, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.45 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Taysha Gene Therapies Inc (NASDAQ: TSHA) saw its 5-day average volume 9.23 million, a positive change from its year-to-date volume of 2.77 million. As of the previous 9 days, the stock’s Stochastic %D was 13.68%. Additionally, its Average True Range was 0.35.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 28.52%, which indicates a significant increase from 16.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 161.58% in the past 14 days, which was higher than the 125.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.94, while its 200-day Moving Average is $2.38. Nevertheless, the first resistance level for the watch stands at $2.34 in the near term. At $2.45, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.58. If the price goes on to break the first support level at $2.10, it is likely to go to the next support level at $1.97. Assuming the price breaks the second support level, the third support level stands at $1.86.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are currently 187,018K shares outstanding in the company with a market cap of 451.09 million. Presently, the company’s annual sales total 15,450 K according to its annual income of -111,570 K. Last quarter, the company’s sales amounted to 3,410 K and its income totaled -24,060 K.
